Potential of Scorpion (Scorpiops pseudomonatus) Venom in Diabetes Therapy: A Study on α-Amylase and α-Glucosidase Inhibition

Introduction: The increasing number of diabetes mellitus patients and the complications of its treatment using chemical medicine have made it necessary to look for new treatment options that can control blood glucose levels. Objective: To explore the possibility of using scorpion venom as an inhibitor of the essential enzymes that hydrolyze carbohydrates, glucosidase and amylase, which are important targets in diabetes treatment. Methodology: Scorpion (Scorpiops pseudomonatus) venom has been evaluated for α-amylase and α-glucosidase inhibitory activities using standardized assays. Venom from selected scorpion species has been assessed for inhibitory activity using in vitro biochemical assays. IC50 values have been determined to evaluate the inhibitory potency and specificity. Results: About 35 scorpion individual species were taken, and 0.3-0.5 milligrams of venom from every scorpion individual were collected. Significant inhibition of both α-amylase α-glucosidase and activities was shown in the results (Amylase: 9.230 ± 2.475 and Glucosidase: 2.753 ± 0.573 IC50 ± STD). Conclusion: According to the results, scorpion (Scorpiops pseudomonatus) venom has the potential to be a unique therapeutic method for controlling blood sugar levels, as it is a promising source of natural enzyme inhibitors.